In our study, we assessed the effects of SETD2 mutations/variants in patients with MDS, and observed that SETD2 deficiency was an IPSS-R-independent factor predicting shorter PFS in both univariate and multivariate analyses. Here, SETD2 is linked to myelodysplastic syndrome.